# US 6,727,276 B2 · Epothilone derivatives for the treatment of refractory tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,276 B2
- Document ID: US6727276B2
- Status: Granted
- Kind: B2
- Application number: 10/071,988
- Filed: 2002-02-08
- Published: 2002-11-07
- Granted: 2004-04-27
- Earliest claimed: 2001-02-20
- Assignees: Bristol-Myers Squibb Company
- Inventors: Francis Y. F. Lee
- Web page: https://patentgrep.com/patent/US6727276B2

## CPC

- A61K 31/425: Thiazoles
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating tumors in a mammal, especially a human that have demonstrated resistance to oncology with taxane oncology agents is disclosed. The method is effective where the tumor has initially been unresponsive to taxane therapy or has developed resistance during the course of treatment. The method comprising the administration of an epothilone derivative selected from those represented by formula I: The subject epothilone derivatives are advantageous in addition to their enhanced potency and effectiveness against tumors that have demonstrated resistance to therapy with taxane oncology agents in that both are efficacious upon oral administration.

## Claims

### Claim 1

A method of treating a tumor in a mammal, said tumor having demonstrated resistance to oncology therapy and sensitive to compounds of Formula I, comprising administering to said mammal an effective amount of a composition comprising a pharmaceutically acceptable carrier and an epothilone compound of formula I:
wherein:
P—Q is a carbon-carbon double bond or an epoxide;
G is
R is selected from the group of H, alkyl, and substituted alkyl;
R1 selected from the group consisting of
R2 is
G1 is selected from the group consisting of H, halogen, CN, alkyl and substituted alkyl;
G2 is selected from the group consisting of H, alkyl, and substituted alkyl;
G3 is selected from the group consisting of O, S, and NZ1;
G4 is selected from the group consisting of H, alkyl, substituted alkyl, OZ2, NZ2Z3, Z2C═O, Z4SO2, and optionally substituted glycosyl;
G5 is selected from the group consisting of halogen, N3, NCS, SH, CN, NC, N(Z1)3+ and heteroaryl, provided that if G1 and G2 are both hydrogen, G5 is not halogen;
G6 is selected from the group consisting of H, alkyl, substituted alkyl, CF3, OZ5, SZ5, and NZ5Z6;
G7 is CZ7 or N;
G8 is selected from the group consisting of H, halogen, alkyl, substituted alkyl, OZ10, SZ10, NZ10Z11;
G9 is selected from the group consisting of O, S, —NH—NH— and —N═N—;
G10 is N or CZ12;
G11 is selected from the group consisting of H2N, substituted H2N, alkyl, substituted alkyl, aryl, and substituted aryl;
each Z1, Z6, Z9, and Z11 is, independently, selected from the group consisting of H, alkyl, substituted alkyl, acyl, and substituted acyl;
Z2 is selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, and heterocycle;
each Z3, Z5, Z8, and Z10 is, independently, selected from the group consisting of H, alkyl, substituted alkyl, acyl, substituted acyl, aryl, and substituted aryl;
Z4 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, and heterocycle;
Z7 is selected from the group consisting of H, halogen, alkyl, substituted alkyl, aryl, substituted aryl, OZ8, SZ8, and NZ8Z9, provided that if G6 and G8 are both H, then Z7 is not also H; and
Z12 is selected from the group consisting of H, halogen, alkyl, substituted alkyl, aryl, and substituted aryl;
with the proviso that when R1 is
G1, G2, G3 and G4 cannot simultaneously have the following meanings:
G1 and G2 are H, G3 is O, and G4 is H or Z2C═O wherein Z2 is an alkyl group,
and pharmaceutically acceptable salts thereof and any hydrates, solvates or geometric, optical and stereoisomers thereof.

### Claim 2 (depends on 1)

The method of claim 1 wherein said compound is of formula Ia:
wherein:
P—Q is a carbon-carbon double bond or an epoxide;
R is H or a methyl group;
G1 is H, an alkyl group, a substituted alkyl group or a halogen atom;
G2 is H, an alkyl group or a substituted alkyl group;
G3 is an O atom, an S atom or an NZ1 group;
Z1 is H, an alkyl group, a substituted alkyl group, an acyl group, or a substituted acyl group;
G4 is H, an alkyl group, a substituted alkyl group, an OZ2 group, an NZ2Z3 group, +Z2C═O group, a Z4SO2 group or an optionally substituted glycosyl group;
Z2 is H, an alkyl group, a substituted alkyl group, an aryl group, a substituted aryl group or a heterocyclic group;
Z3 is H, an alkyl group, a substituted alkyl group, an acyl group or a substituted acyl group; and
Z4 is alkyl, a substituted alkyl, an aryl, a substituted aryl or a heterocyclic group;
with the proviso that G1, G2, G3 and G4 cannot simultaneously have the following meanings:
G1 and G2 are H, G3 is O, and G4 is H or Z2C═O wherein Z2 is an alkyl group.

### Claim 3 (depends on 1)

The method of claim 1 wherein said compound is of formula Ib:
wherein:
P—Q is a carbon-carbon double bond or an epoxide;
R is H or a methyl group;
G1 is H, an alkyl group, a substituted alkyl group or a halogen atom;
G2 is H, an alkyl group or a substituted alkyl group; and
G5 is an N3 group, an NCS group, an SH group, a CN group, an NC group or a heterocyclic group.

### Claim 4 (depends on 1)

The method of claim 1 wherein said compound is of formula IIa:
wherein:
P—Q is a carbon-carbon double bond or an epoxide;
R is H or a methyl group;
G6 is H, an alkyl group, a substituted alkyl group or a CF3, OZ5, SZ5 or NZ5Z6 group;
Z5 is H, an alkyl group, a substituted alkyl group, an acyl group or a substituted acyl group;
Z6 is H, an alkyl group or a substituted alkyl group;
G7 is a CZ7 group or a N atom;
Z7 is H, halogen atom, an alkyl group, a substituted alkyl group, an aryl group, or a substituted aryl group, or an OZ8, SZ8 or NZ8Z9 group;
Z8 is H, an alkyl group, a substituted alkyl group, an acyl group or a substituted acyl group;
Z9 is H, an alkyl group or a substituted alkyl group;
G8 is H, a halogen atom, an alkyl group, a substituted alkyl group or an OZ10, SZ10 or NZ10Z11 group, provided that G6, G8 and Z7 are not all H;
Z10 is H, an alkyl group, a substituted alkyl group, an acyl group, a substituted acyl group, an aryl group, or a substituted aryl group; and
Z11 is H, an alkyl group, a substituted alkyl group, an acyl group, or a substituted acyl group.

### Claim 5 (depends on 1)

The method of claim 1 wherein said compound is of formula IIb:
wherein:
P—Q is a carbon-carbon double bond or an epoxide;
R is H or a methyl group;
G6 is H, an alkyl group, a substituted alkyl group or a CF3, OZ5, SZ5 or NZ5Z6 group;
Z5 is H, an alkyl group, a substituted alkyl group, an acyl group or a substituted acyl group;
Z6 is H, an alkyl group or a substituted alkyl group; and
G9 is O, S or an —N═N— group.

### Claim 6 (depends on 1)

The method of claim 1 wherein said compound is of formula III:
wherein:
P—Q is a carbon-carbon double bond or an epoxide;
R is H or a methyl group;
G10 is an N atom or a CZ12 group; and
Z12 is H, a halogen atom, an alkyl group, a substituted alkyl group, an aryl group, or a substituted aryl group.

### Claim 7 (depends on 1)

The method of claim 1 wherein said compound is of formula IV:
wherein:
P—Q is a carbon-carbon double bond or an epoxide;
R is H or a methyl group; and
G11 is an H2N group, a substituted H2N group, an alkyl group, a substituted alkyl group, an aryl group or a substituted aryl group.

### Claim 8 (depends on 1)

The method of claim 1 wherein said compound is selected from the group consisting of:
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(azidomethyl)-4-thiazolyl]-1-methylethenyl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo-[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-aminomethyl-4-thiazolyl)ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-4-thiazolyl]-1-methylethenyl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[4S-[4R*,7S*,8R*,9R*,15R*(E)]]-16-[2-[2-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-4-thiazolyl]-1-methyl-ethenyl]-4,8-dihydroxy-5,5,7,9,13-pentamethyl-1-oxa-13(Z)-cyclohexadecene-2,6-dione;
[4S-[4R*,7S*,8R*,9R*,15R*(E)]]-16-[2-[2-(aminomethyl)-4-thiazolyl]-1-methylethenyl]-4,8-dihydroxy-5,5,7,9,13-pentamethyl-1-oxa-13(Z)-cyclohexadecene-2,6-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-8,8,10,12-tetramethyl-3-[1-methyl-2-[2-[(pentanoyloxy)methyl]-4-thiazolyl]ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-8,8,10,12-tetramethyl-3-[1-methyl-2-[2-[(naphthoyloxy)methyl]-4-thiazolyl]ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-3-[2-[2-[[(2-methoxyethoxy)acetyloxy]methyl]-1-methyl-4-thiazolyl]ethenyl]-8,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-8,8,10,12-tetramethyl-3-[1-methyl-2-[2-[(N-propionylamino)methyl]-4-thiazolyl]ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-(3-acetyl-2,3-dihydro-2-methylene-4-thiazolyl)-1-methylethenyl]-7,11-dihydroxy-8,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione, N-oxide;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-3-[2-[2-(methoxymethyl)-4-thiazolyl]-1-methylethenyl]-8,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-[2-(phenoxymethyl)-4-thiazolyl]ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-[(ethylthio)methyl]-4-thiazolyl]-1-methylethenyl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(ethoxymethyl)-4-thiazolyl]-1-methylethenyl]-7,11-dihydroxy-8,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-8,8,10,12-tetramethyl-3-[1-methyl-2-[2-[(2,3,4,6-tetraacetyl-alpha-glucosyloxy)methyl]-4-thiazolyl]ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-8,8,10,12-tetramethyl-3-[1-methyl-2-[2-[(2′,3′,4′,6′-tetraacetyl-beta-glucosyloxy)methyl]-4-thiazolyl]ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-8,8,10,12-tetramethyl-3-[1-methyl-2-[2-[(6′-acetyl-alpha-glucosyloxy)methyl]-4-thiazolyl]ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-[2-[p-toluenesulfonyloxy)methyl]-4-thiazolyl]ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(bromomethyl)-4-thiazolyl]-1-methylethenyl]-7,11-dihydroxy-8,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-(5-bromo-2-methyl-4-thiazolyl)-1-methylethenyl]-7,11-dihydroxy-8,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(cyanomethyl)-4-thiazolyl]-1-methylethenyl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[4S-[4R*,7S*,8R*,9R*,15R*(E)]]-16-[2-[2-(cyanomethyl)-4-thiazolyl]-1-methylethenyl]-4,8-dihydroxy-5,5,7,9,13-pentamethyl-1-oxa-13(Z)-cyclohexadecene-2,6-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-3-[2-[2-(1H-imidazol-1-ylmethyl)-4-thiazolyl]-1-methylethenyl]-8,8,10,12-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-(2-formyl-4-thiazolyl)-1-methylethenyl]-7,11-dihydroxy-8,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-(2-formyl-4-thiazolyl)-1-methylethenyl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-(2-ethenyl-4-thiazolyl)-1-methylethenyl]-7,11-dihydroxy-8,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-3-[2-[2-(methoxyimino)-4-thiazolyl]-1-methylethenyl]-8,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-8,8,10,12-tetramethyl-3-[1-methyl-2-[2-[[(phenylmethyl)imino]methyl]-4-thiazolyl]ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-(2-acetyl-4-thiazolyl)-1-methylethenyl]-7,11-dihydroxy-8,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-8,8,10,12-tetramethyl-3-[1-methyl-2-(2-oxiranyl-4-thiazolyl)ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-3-[2-[2-(2-iodoethenyl)-4-thiazolyl]-1-methylethenyl]-8,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-(2-ethynyl-4-thiazolyl)-1-thiazolyl)-1-methylethenyl]-7,11-dihydroxy-8,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-[2-[(methylamino)methyl]-4-thiazolyl]ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-[[[2-(dimethylamino)ethyl]amino]methyl]-4-thiazolyl]-1-methylethenyl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-[(dimethylamino)methyl]-4-thiazolyl]-1-methylethenyl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-[[bis(2-methoxyethyl)amino]methyl]-4-thiazolyl]-1-methylethenyl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-[2-[(4-methyl-1-piperazinyl)methyl]-4-thiazolyl]ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-4-[2-(7,11-dihydroxy-8,8,10,12-tetramethyl-5,9-dioxo-4,17-dioxabicyclo[14.1.0]heptadecan-3-yl)-1-propenyl]-2-thiazolecarboxylic acid; and
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-4-[2-(7,11-dihydroxy-8,8,10,12-tetramethyl-5,9-dioxo-4,17-dioxabicyclo[14.1.0]heptadecan-3-yl)-1-propenyl]-2-thiazolecarboxylic acid methyl ester.

### Claim 9 (depends on 8)

The method of claim 8 wherein said compound is
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-aminomethyl-4-thiazolyl)ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione.

### Claim 10 (depends on 1)

The method of claim 1 wherein said epothilone compound is of formula:

### Claim 11 (depends on 1)

The method of claim 1 wherein said mammal is a human.

### Claim 12 (depends on 1)

The method of claim 1 wherein the composition containing said epothilone compound is administered parenterally.

### Claim 13 (depends on 12)

The method of claim 12 wherein said epothilone compound is of formula:

### Claim 14 (depends on 1)

The method of claim 1 wherein the composition containing said epothilone compound is administered orally.

### Claim 15 (depends on 14)

The method of claim 14 wherein said epothilone compound is of formula:

### Claim 16 (depends on 1)

The method of claim 1 wherein said tumor was initially not responsive to oncology therapy.

### Claim 17 (depends on 1)

The method of claim 1 wherein said tumor was initially responsive to oncology therapy, but developed resistance thereto during the course of treatment.

### Claim 18 (depends on 1)

The method of claim 1 wherein said compound is administered simultaneously or sequentially with a chemotherapeutic agent useful in the treatment of cancer or other proliferative diseases.

### Claim 19 (depends on 1)

The method of claim 1 wherein said tumor was initially not responsive to oncology taxane therapy.

### Claim 20 (depends on 1)

The method of claim 1 wherein said tumor was initially responsive to oncology taxane therapy but developed resistance thereto during the course of treatment.
